Denamarin References

Denamarin References

1. 1. McMichael MA. Oxidative stress, antioxidants, and assessment of oxidative stress in dogs and cats. J Am Vet Med Assoc 2007; 231(5): 714-720.
2. 2. Barry-Heffernan C, Ekena J, Dowling S, Pinkerton ME, Viviano K. Biomarkers of oxidative stress as an assessment of the redox status of the liver in dogs. J Vet Int Med 2019; 33(2): 611-617.
3. 3. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y. The role of oxidative stress and antioxidants in liver diseases. Int J Mol Sci 2015; 16(11): 26087-26124.
4. 4. Castillo Rodríguez C, Wittwer Menge F, Cerón, JJ. Oxidative stress in veterinary medicine. Vet Med Int 2011; 812086.
5. 5. Webb C, Twedt D. Oxidative stress and liver disease. Vet Clin North Am Small Anim Pract 2008; 38(1): 125-135.
6. 6. Mato JM, Corrales F, Martin-Duce A, Ortiz P, Pajares MA, Cabrero C. Mechanisms and consequences of the impaired trans-sulphuration pathway in liver disease: Part I: Biochemical implications. Drugs 1990; 40: 58-64.
7. 7. Werge MP, McCann A, Galsgaard ED, et al. The role of the transsulfuration pathway in non-alcoholic fatty liver disease. J Clin Med 2021; 10(5): 1081.
8. 8. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol 2012; 57(5): 1097-1109.
9. 9. Webster CR, Center SA, Cullen JM, et al. ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs. J Vet Int Med 2019; 33(3): 1173-1200.
10. 10. Center SA. S-adenosyl-methionine (SAMe) an antioxidant and anti-inflammatory nutraceutical. In: Proceedings from the 18th Annual ACVIM Forum 2000: 550-552.
11. 11. Center SA, Randolph JF, Warner KL, et al. The effects of S-adenosylmethionine on clinical pathology and redox potential in the red blood cell, liver, and bile of clinically normal cats. J Vet Intern Med 2005; 19(3): 303-314.
12. 12. Data on file – Nutramax Laboratories
13. 13. Center SA, Warner KL, McCabe J, Foureman P, Hoffmann WE, Erb HN. Evaluation of the influence of S-adenosylmethionine on systemic and hepatic effects of prednisolone in dogs. Am J Vet Res 2005; 66: 330-341.
14. 14. Senthilkumar UP, Padmanabhan R, Sivasankaran V, Mohan S. Chemical synthesis of S-adenosyl-L-methionine with enrichment of (S,S)-isomer. United States Patent: US 7,667,034 B2, 2010 https://patents.google.com/patent/US7667034B2/en (accessed March 6, 2024).
15. 15. Benedetti A, Sivieri L. Dried, freeze-dried and/or microencapsulated Saccharomyces cerevisiae cells with a high content of (S)-(+)-S-adenosyl-L-methionine. European Patent Office Publ. of Application with search report EP20050425413, 2005.
16. 16. Dejima H, Kobayashi M, Takasaki H, Takeda N, Shirahata A, Samejima K. Synthetic decarboxylated S-adenosyl-L-methionine as a substrate for aminopropyl transferases. Biol Pharm Bull 2003; 26(7): 1005-1008.
17. 17. Dunne JB, Alexander B, Williams R, Tredger JM. Evidence that S-adenosyl-L-methionine diastereoisomers may reduce ischaemia-reperfusion injury by interacting with purinoceptors in isolated rat liver. Br J Pharmacol 1998; 125(1): 225-233.
18. 18. Bottiglieri T, Gerbarg PL, Brown RP. S-adenosylmethionine. In: Gerbarg PL, Muskin PR, Brown RP, eds. Complementary and Integrative Treatments in Psychiatric Practice. Arlington, VA: American Psychiatric Association Publishing, 2017: 41-52.
19. 19. Sturgess CP. Measurement of the S-adenosyl methionine (SAMe) content in a range of commercial veterinary SAMe supplements. J Small Anim Pract 2014; 55(9): 447-450.
20. 20. Kvasnicka F, Bíba B, Sevcík R, Voldrich M, Kratka J. Analysis of the active components of silymarin. J Chromatogr A 2003; 990: 239-245.
21. 21. Filburn CR, Kettenacker R, Griffin DW. Safety and bioavailability in Beagles of zinc and vitamin E combined with silybin and phosphatidylcholine. Intern J Appl Res Vet Med 2006; 4: 326-334.
22. 22. Comoglio A, Leonarduzzi G, Carini R, et al. Studies on the antioxidant and free radical scavenging properties of IdB 1016 a new flavanolignan complex. Free Radic Res Commun 1990; 11: 109-115.
23. 23. Bosisio E, Benelli C, Pirola O. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res 1992; 25: 147-154.
24. 24. Sonnebichler J, Zetl I. Mechanism of action of silibinin. V. Effect of silibinin on the synthesis of ribosomal RNA, mRNA and tRNA in rat liver in vivo. Hoppe Seylers Z Physiol Chem 1984; 365: 555-566.
25. 25. Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996; 23: 749-754.
26. 26. Crocenzi FA, Pellegrino JM, Sánchez Pozzi EJ, Mottino AD, Garay EA, Roma MG. Effect of silymarin on biliary bile salt secretion in the rat. Biochem Pharmacol 2000; 59: 1015-1022.
27. 27. Valenzuela A, Aspillaga M, Vial S, Guerra R. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Med 1989; 55: 420-422.
28. 28. Filburn CR, Kettenacker R, Griffin DW. Bioavailability of a silybin-phosphatidylcholine complex in dogs. J Vet Pharmacol Therap 2007; 30: 132-138.
29. 29. Balouei F, Stefanon B, Martello E, et al. Supplementation with Silybum marianum extract, synbiotics, omega-3 fatty acids, vitamins, and minerals: impact on biochemical markers and fecal microbiome in overweight dogs. Animals 2024; 14, 579.
30. 30. Fukui H. Gut-liver axis in liver cirrhosis: how to manage leaky gut and endotoxemia. World J Hepatol 2015; 7(3): 425.
31. 31. Habermaass V, Olivero D, Gori E, Mariti C, Longhi E, Marchetti V. Intestinal microbiome in dogs with chronic hepatobiliary disease: can we talk about the gut–liver axis? Animals 2023; 13(20): 3174.
32. 32. Yi J, Li Y, Mai Q, et al. Hepatotoxicity and the role of the gut–liver axis in dogs after oral administration of zinc oxide nanoparticles. Metallomics 2022; 14(11): mfac066.
33. 33. Paris S, Chapat L, Pasin M, et al. β-glucan-induced trained immunity in dogs. Front Immunol 2020; 11: 566893.
34. 34. Pawar MM, Pattanaik AK, Sinha DK, Goswami TK, Sharma K. Effect of dietary mannanoligosaccharide supplementation on nutrient digestibility, hindgut fermentation, immune response and antioxidant indices in dogs. J Anim Sci Technol 2017; 59: 1-7.
35. 35. Lin CY, Carroll MQ, Miller MJ, Rabot R, Swanson KS. Supplementation of yeast cell wall fraction tends to improve intestinal health in adult dogs undergoing an abrupt diet transition. Front Vet Sci 2020; 7: 597939.
36. 36. Haladová E, Mojžišová J, Smrco P, et al. Immunomodulatory effect of glucan on specific and nonspecific immunity after vaccination in puppies. Acta Vet Hung 2011; 59(1): 77-86.
37. 37. Stuyven E, Verdonck F, Van Hoek I, et al. Oral administration of beta-1,3/1,6-glucan to dogs temporally changes total and antigen-specific IgA and IgM. Clin Vaccine Immunol 2010; 17(2): 281-285.
38. 38. Hoving LR, van der Zande HJP, Pronk A, Guigas B, Willems van Dijk K, van Harmelen V. Dietary yeast-derived mannan oligosaccharides have immune-modulatory properties but do not improve high fat diet-induced obesity and glucose intolerance. PLoS One 2018; 13(5): e0196165.
39. 39. Marchi PH, Vendramini TH, Zafalon RV, et al. Effects of increasing levels of purified beta-1, 3/1, 6-glucans on the fecal microbiome, digestibility, and immunity variables of healthy adult dogs. Microorganisms 2024; 12(1): 113.
40. 40. Grieshop C, Flickinger E, Bruce K, Patil AR, Czarnecki-Maulden GL, Fahey Jr GC. Gastrointestinal and immunological responses of senior dogs to chicory and mannan-oligosaccharides. Arch Anim Nutr 2004; 58(6): 483-494.
41. 41. Newman KE, Newman MC. Evaluation of mannanoligosaccharide on the microflora and immunoglobulin status of sows and piglet performance. J Anim Sci 2001; 79: 189-191.
42. 42. Spring P, Wenk C, Connolly A, Kiers A. A review of 733 published trials on Bio-Mos®, a mannan oligosaccharide, and Actigen®, a second generation mannose rich fraction, on farm and companion animals. J Appl Anim Nutr 2015; 3: e8.